Actively Recruiting

Phase 3
Age: 18Years - 55Years
All Genders
NCT06247839

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Led by Sharmin Ghaznavi · Updated on 2025-05-06

20

Participants Needed

1

Research Sites

94 weeks

Total Duration

On this page

Sponsors

S

Sharmin Ghaznavi

Lead Sponsor

C

COMPASS Pathways

Collaborating Sponsor

AI-Summary

What this Trial Is About

This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.

CONDITIONS

Official Title

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Who Can Participate

Age: 18Years - 55Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to provide informed consent and understand the study requirements
  • Age between 18 and 55 years at screening
  • Diagnosed with at least moderate Major Depressive Disorder (single or recurrent episode) lasting 3 months to 3 years if single episode
  • Score of 18 or higher on the Hamilton Depression Rating Scale with Atypical Depression Supplement at screening and baseline
  • Have not responded to 1 to 4 adequate pharmacological treatments for the current depressive episode
  • Score less than 7 on the McLean Screening Instrument for Borderline Personality Disorder at screening
  • Completed supervised tapering off of all psychotropic medications at least 2 weeks before baseline scan
  • Score over 40 on the Wechsler Test of Adult Reading
  • Right-handed as determined by the Edinburgh Handedness Inventory
  • Able to complete all required assessments independently and comply with study visits
  • Have ongoing established mental health care
Not Eligible

You will not qualify if you...

  • Current, past, or family history of schizophrenia, psychotic disorders (unless substance induced or medical), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or serious psychiatric comorbidity
  • Positive MRI screening due to metal implant, claustrophobia, or similar issues
  • Prior electroconvulsive therapy or ketamine treatment for current episode
  • Current cognitive behavioral therapy (CBT) that is not stable throughout the study or started within 21 days of baseline
  • Alcohol or substance abuse within the last year
  • Significant suicide risk as assessed by clinical interview or suicide rating scales within the past year
  • Significant homicide risk as assessed by clinical interview
  • Depression caused by other serious medical conditions
  • Daily use of benzodiazepines
  • Personal behavior or circumstances incompatible with safe psilocybin exposure; use of psilocybin or psychedelics within one year
  • Women who are pregnant, breastfeeding, or planning pregnancy; sexually active women must use effective contraception and have negative pregnancy tests at screening and day before treatment
  • Cardiovascular conditions including recent stroke or heart attack within one year, high blood pressure, arrhythmia, anticoagulant therapy, or aneurysm
  • Uncontrolled insulin-dependent diabetes
  • Seizure disorders
  • Positive drug screen for illicit or abused drugs at screening and day before treatment
  • History of brain surgery, meningitis, degenerative CNS disorders, epilepsy, intellectual disability, significant head trauma within 2 years, or CNS injury
  • Physical conditions that may pose risk or interfere with study interpretation
  • Current enrollment or participation in investigational drug/device studies within 6 months
  • Current enrollment or participation in interventional depression studies within 6 months
  • Non-native English speakers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Athinoula A. Martinos Center for Biomedical Imaging

Charlestown, Massachusetts, United States, 02129

Actively Recruiting

Loading map...

Research Team

S

Sarah G Richter, M.A.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here